Gubra Revenue and Competitors

Claim your profile

Hoersholm, Denmark

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Gubra's estimated annual revenue is currently $31.9M per year.(i)
  • Gubra's estimated revenue per employee is $155,000

Employee Data

  • Gubra has 206 Employees.(i)
  • Gubra grew their employee count by 23% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$7910M193245%$204.3MN/A
#2
$31.9M20623%N/AN/A
#3
$3.4M88123%$85.7MN/A
#4
$13.2M39-83%$263.3MN/A
#5
$16.1M10416%N/AN/A
#6
$2.6M1755%N/AN/A
#7
$8.7M56409%N/AN/A

Founded in 2008, we are a privately-held biotech company with two primary areas of business: Pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. Our focus is the metabolic space (obesity, diabetes, NASH and gastrointestinal diseases), where we specialize in in vivo pharmacology, peptide chemistry, molecular pharmacology, histology, imaging, stereology, NGS (next generation sequencing), bioinformatics and ex vivo assays. Gubra is an abbreviation for GUt and BRAin, the original key focus areas of our research and expertise. We work with some of the most interesting and loyal partners and customer from across the world within big pharma, biotech and academia. Through a constant focus on high quality, scientific excellence, speed and solid teamwork, we have established ourselves as a highly professional and competent partner in the market.

keywords:N/A

N/A

Total Funding

206

Number of Employees

$31.9M

Revenue (est)

23%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Gubra News

2019-05-30 - Boehringer adds to obesity alliance with Denmark's Gubra

Two years after they started working together, Boehringer Ingelheim and Gubra have taken their obesity collaboration to a higher level.

2019-05-29 - Boehringer Ingelheim and Gubra announce new collaboration ...

INGELHEIM, Germany & HØRSHOLM, Denmark--(BUSINESS WIRE)--Boehringer Ingelheim and Gubra announce a second collaboration and ...

2019-05-29 - Gubra to get up to 240 million euros in new Boehringer deal

German pharma major Boehringer Ingelheim and Danish biotech Gubra have announced a second collaboration and license agreement for ...